Investment Rating - The investment rating for the company is "Outperform the Market" [5][3][20] Core Views - The company achieved steady growth in the first three quarters of 2025, with revenue reaching 4.63 billion yuan (+11.82%) and net profit attributable to shareholders at 800 million yuan (+12.66%) [1][6] - Emerging businesses are becoming the core growth engine, with a significant increase in revenue from new business areas, particularly in chemical macromolecules, which saw over 150% growth [2][3] - The company is expected to maintain rapid revenue growth throughout 2025, with projected revenues of 6.68 billion yuan, 7.53 billion yuan, and 8.29 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 15%, 13%, and 10% [3][4] Financial Performance Summary - For the first three quarters of 2025, the company reported quarterly revenues of 1.54 billion yuan, 1.65 billion yuan, and 1.44 billion yuan for Q1, Q2, and Q3 respectively, with Q2 showing the highest growth at +26.95% [1][6] - The operating cash flow improved to 1.144 billion yuan (+8.38%), indicating enhanced operational efficiency and effective cost control [2][12] - The gross margin for the small molecule CDMO business was 47.0% (-1.9pp), while the emerging business gross margin was 30.6% (+10.6pp) [2][3] Earnings Forecast - The company forecasts net profits of 1.14 billion yuan, 1.29 billion yuan, and 1.46 billion yuan for 2025, 2026, and 2027 respectively, with expected growth rates of 20%, 14%, and 14% [3][4] - The current price-to-earnings ratio (PE) is projected to be 29.8, 26.3, and 23.1 for the years 2025, 2026, and 2027 respectively [3][4]

Group 1 - JPMorgan Chase & Co. increased its stake in Kelaiying (06821.HK) by acquiring 155,800 shares at an average price of HKD 82.7632 per share, totaling approximately HKD 12.89 million [1] - Following this acquisition, JPMorgan's total holdings in Kelaiying rose to 2,326,842 shares, increasing its ownership percentage from 7.87% to 8.44% [1][2]

Group 1 - JPMorgan Chase & Co. increased its stake in Kailaiying (06821.HK) by purchasing 155,800 shares at an average price of HKD 82.7632 per share, totaling approximately HKD 12.8945 million [1] - Following this transaction, JPMorgan's total holdings in Kailaiying rose to 2,326,842 shares, increasing its ownership percentage from 7.87% to 8.44% [1]

Core Viewpoint - Morgan Stanley increased its stake in Kelaiying (002821)(06821) by 155,800 shares at a price of HKD 82.7632 per share, totaling approximately HKD 12.8945 million, raising its total holdings to about 2.3268 million shares, which represents a holding percentage of 8.44% [1] Summary by Category - **Investment Activity** - Morgan Stanley's recent purchase of 155,800 shares indicates a strategic move to increase its investment in Kelaiying [1] - The total investment amount for this transaction was approximately HKD 12.8945 million [1] - **Shareholding Details** - Following the increase, Morgan Stanley's total shareholding in Kelaiying is now approximately 2.3268 million shares [1] - The updated shareholding percentage stands at 8.44% [1]

Group 1 - Morgan Stanley increased its stake in Kairui Ying (06821) by 155,800 shares at a price of HKD 82.7632 per share, totaling approximately HKD 12.8945 million [1] - After the increase, the total number of shares held by Morgan Stanley is approximately 2.3268 million, representing a holding percentage of 8.44% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | 備註： 第 1 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 本月底法定/註冊股本總額： RMB 360,593,720 備註： 第 1 頁 共 11 頁 v 1.1.1 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, particularly recommending a focus on innovative drugs and sectors with improving performance such as medical devices and CXO [1][10]. Core Insights - The pharmaceutical sector in Q3 2025 showed signs of recovery with a year-on-year revenue growth of 0.6% in Q3, marking the first positive growth in four quarters [1][10]. - Innovative drugs demonstrated a remarkable revenue growth of 36% in Q3 2025, with a turnaround in net profit from a loss of 500 million to a profit of 1.5 billion [10]. - The CXO sector also showed strong performance with a revenue growth of 10.9% and a net profit increase of 47.7% year-on-year, indicating a trend reversal [10]. Summary by Sections Q3 2025 Performance - The A-share pharmaceutical sector, excluding certain companies, achieved total revenue of 1,806.4 billion with a year-on-year decline of 1.9% and a net profit of 139.2 billion, down 5.1% year-on-year [2][11]. - In Q3 2025, total revenue reached 600.4 billion, reflecting a year-on-year increase of 0.6% but a quarter-on-quarter decrease of 0.4% [2][11]. Profitability and Margins - The gross profit for the pharmaceutical sector in Q3 2025 was 189.1 billion, with a gross margin of 31.5%, slightly down from the previous year [5][8]. - The overall net profit margin for Q3 2025 was 6.8%, showing a slight decline compared to the previous year [8]. Cash Flow - The sector reported a net cash inflow from operating activities of 59.1 billion in Q3 2025, representing a year-on-year growth of 17.9% [7][13]. Subsector Performance - The innovative drug sector's revenue growth of 36% and the CXO sector's revenue growth of 10.9% highlight the strong recovery and growth potential within these subsectors [10][11]. - The report emphasizes the importance of focusing on companies such as 恒瑞医药, 长春高新, and 药明康德, which are expected to perform well in the current market environment [1][10].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, indicating a positive outlook for the sector compared to the overall market performance [22]. Core Insights - The pharmaceutical sector has shown signs of recovery, with the first positive year-on-year revenue growth in four quarters, driven by strong performances in the innovative drug and CXO segments [2][11]. - Innovative drugs achieved a remarkable 36% revenue growth in Q3 2025, transitioning from a loss of 500 million to a profit of 1.5 billion, highlighting the sector's high growth potential [11]. - The CXO segment has also shown a significant turnaround, with a year-on-year revenue growth of 10.9% and a net profit increase of 47.7%, expected to maintain mid-to-high growth in the coming year [11]. Summary by Sections Industry Performance - In the first three quarters of 2025, the A-share pharmaceutical and biotechnology sector, excluding certain companies, generated total revenue of 1,806.4 billion yuan, a year-on-year decrease of 1.9%, and a net profit of 139.2 billion yuan, down 5.1% [2][3]. - For Q3 2025, total revenue reached 600.4 billion yuan, reflecting a year-on-year increase of 0.6% but a quarter-on-quarter decrease of 0.4% [2][3]. Profitability Metrics - The gross profit for Q3 2025 was 189.1 billion yuan, with a gross margin of 31.5%, showing a slight decline compared to previous periods [5][8]. - The overall net profit margin for the sector in Q3 2025 was 6.8%, down 0.05 percentage points year-on-year and 1.47 percentage points quarter-on-quarter [8]. Cash Flow Analysis - The sector reported a net cash inflow from operating activities of 59.1 billion yuan in Q3 2025, marking a year-on-year increase of 17.9% and achieving positive growth for two consecutive quarters [7][14]. Subsector Performance - The report highlights the strong performance of the innovative drug and CXO subsectors, with innovative drugs showing a significant recovery and CXO experiencing a positive trend reversal [11][12].

Core Viewpoint - Kailaiying's stock price has experienced fluctuations, with a year-to-date increase of 29.29% but a recent decline of 11.92% over the past 60 days, indicating potential volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, Kailaiying achieved a revenue of 4.63 billion yuan, representing a year-on-year growth of 11.82%. The net profit attributable to shareholders was 800 million yuan, reflecting a growth of 12.66% [2]. - Since its A-share listing, Kailaiying has distributed a total of 2.405 billion yuan in dividends, with 1.701 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of Kailaiying's shareholders reached 60,100, an increase of 45.37% compared to the previous period. The average circulating shares per person remained at 0 shares [2]. - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]. Market Activity - On November 4, Kailaiying's stock price fell by 2.02%, trading at 96.96 yuan per share, with a total market capitalization of 34.963 billion yuan. The stock saw a net outflow of 3.0292 million yuan in principal funds [1]. - The stock has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on August 8, where it recorded a net buy of -180 million yuan [1]. Business Overview - Kailaiying Pharmaceutical Group, established on October 7, 1998, and listed on November 18, 2016, primarily provides CMO pharmaceutical outsourcing services. The revenue composition includes 76.19% from small molecule CDMO solutions and 23.71% from emerging services [1][2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing [2].